[Early-summer meningo-encephalitis (ESME) and ESME-vaccination: status 2000].
Tick-borne encephalitis (TBE) is a public health problem very well under control in Austria because of a vaccination programme using a safe, efficient and well tolerated vaccine and a carefully designed social marketing concept. The Austrian vaccine underwent another technological updating and is now marketed under a new brand name (TicoVac) on the basis of an EU registration. A second product is also available (Encepur), but some limitations of use have to be taken into account. To improve the epidemiological situation even further (only 41 hospital cases in 1999) special attention has to be given to the age group 50 years and older as this is the segment of the population where the majority of cases is observed. TBE is a growing international health problem as awareness increases and cases are identified in many European countries, even in regions where TBE so far was not diagnosed. An "International Scientific Working-group on Tick-borne encephalitis (ISW-TBE)" was established to coordinate research and public health activities.
Kunze
U
U
Institut für Sozialmedizin, Universität Wien. Sozialmedizin@univie.ac.at
Bernhard
G
G
Böhm
G
G
Groman
E
E
D000328:Adult; D000368:Aged; D001317:Austria / Q000453:epidemiology; D002648:Child; D004675:Encephalitis, Tick-Borne / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control*; D005060:Europe / Q000453:epidemiology; D006801:Humans; D008590:Meningoencephalitis / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control*; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D012621:Seasons; D014195:Travel; D015164:Vaccines, Inactivated / Q000008:administration & dosage; D014765:Viral Vaccines / Q000008:administration & dosage*
D015164:Vaccines, Inactivated; D014765:Viral Vaccines